Additionally, ELAVL1 has been implicated in the development of resistance to cancer therapies in several malignancies, including PCa (58), pancreatic cancer (59), oral cancer (60), and colorectal cancer (61). This evidence concerns the gene ELAVL1 and pancreatic neoplasm.